Nucala 100 mg powder for solution for injection

DRUG4 trials

Sponsors

Rigshospitalet, Sint Franciscus Vlietland Groep Stichting, Assistance Publique Hopitaux De Paris

Conditions

Chronic rhinosinusitis with nasal polyposisChronic rrhinosinusitis with nasal polypsEosinophilic granulomatosis with polyangiitis (EGPA)Severe asthmaformerly called Churg-Strauss syndrome

Phase 3

BIomarker-dRiven Dosing Interval Extension of biologics in asthma (the BIRDIE trial)

RecruitingCTIS2023-505839-12-01

Sint Franciscus Vlietland Groep StichtingSevere asthma

Start: 2024-02-26Target: 80Updated: 2025-12-03

E-merge - Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study

CompletedCTIS2024-513653-75-00

Assistance Publique Hopitaux De ParisEosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome

Start: 2022-05-30End: 2025-09-05Target: 100Updated: 2025-08-12

Phase 4

Treatment of rhinosinusitis with nasal polyposis with dupilumab and mepolizumab: A randomized, multi-centre, head-to-head comparison in real-world Danish patients

Active, not recruitingCTIS2022-502250-14-00

RigshospitaletChronic rhinosinusitis with nasal polyposis

Start: 2023-04-13Target: 220Updated: 2025-10-29

English title: Complete remission study Subtitle: Discontinuation of Mepolizumab or Dupilumab after at least 12 months without symptoms in patients with severe Chronic rhinosinusitis with polyps – a National Danish RCT study.

RecruitingCTIS2024-519628-25-00

RigshospitaletChronic rrhinosinusitis with nasal polyps

Start: 2025-04-03Target: 66Updated: 2025-11-13